Federated Hermes Inc. Has $7.64 Million Holdings in LivaNova PLC (NASDAQ:LIVN)

Federated Hermes Inc. lessened its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 4.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 139,331 shares of the company’s stock after selling 6,364 shares during the quarter. Federated Hermes Inc. owned 0.26% of LivaNova worth $7,638,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in LIVN. Norges Bank acquired a new stake in LivaNova during the 4th quarter worth $26,064,000. Great Lakes Advisors LLC bought a new position in LivaNova during the 2nd quarter worth about $16,614,000. Mesirow Institutional Investment Management Inc. bought a new position in LivaNova during the 1st quarter worth about $13,816,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in LivaNova during the 4th quarter worth about $8,330,000. Finally, Magnetar Financial LLC increased its holdings in LivaNova by 24.5% during the 1st quarter. Magnetar Financial LLC now owns 753,338 shares of the company’s stock worth $42,142,000 after purchasing an additional 148,178 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Needham & Company LLC increased their target price on LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Stifel Nicolaus increased their target price on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Robert W. Baird upgraded LivaNova from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $55.00 to $66.00 in a report on Tuesday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $70.80.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $51.00 on Wednesday. LivaNova PLC has a fifty-two week low of $42.75 and a fifty-two week high of $64.47. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of -85.00 and a beta of 1.00. The business has a 50-day moving average of $48.86 and a 200-day moving average of $53.44. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.45 and a quick ratio of 2.94.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The business had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. As a group, sell-side analysts predict that LivaNova PLC will post 2.58 earnings per share for the current fiscal year.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.